Exclusive Coverage of the American Association for the Study of Liver Diseases (AASLD) 2025 Meeting
Coverage of the American Association for the Study of Liver Diseases (AASLD) 2025 Meeting, held November 7-11, 2025, in Washington, DC.
Redefining Hemophilia Management: Treatment Goals, Nonfactor Replacement Therapies, and the Role of Fitusiran
Real-World Insights on Biomarker Testing Patterns and Implications for mNSCLC Therapy Selection
Universal Lp(a) Screening and Improved LDL-C Management to Reduce Cardiovascular Costs
Designing Coverage Policies That Keep Pace With Precision Medicine: Integrating Clinical and Economic Evidence for Advanced NSCLC
Immune Thrombocytopenia: Contemporary Pathophysiology, Treatment Gaps, and the Role of Novel Mechanisms in Patient-Centered Care
Exclusive Coverage of the American Heart Association (AHA) Scientific Sessions 2025
Coverage of the American Heart Association Scientific Sessions 2025, November 7-10, 2025, New Orleans, Louisiana.
Navigating Policy and Utilization Management Oncology: Aligning Evidence With Access
Exclusive Coverage of the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 Meeting
Coverage of the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 Meeting, held October 27-30, 2025, in National Harbor, Maryland.
2025 Year in Review: Respiratory
The Transformative Approach of TEVIMBRA® (tislelizumab-jsgr) in Managing ESCC and GC/GEJC
2025 Year in Review: Multiple Myeloma
2025 Year in Review: Non–Small Cell Lung Cancer
Volume: 31
2025 Year in Review: Idiopathic Pulmonary Fibrosis
Expert Consensus on Essential Characteristics of Oncology Value-Based Payment
The Evolving Role of Subcutaneous Therapies in EGFR+ NSCLC
The Burden of the Rare Kidney Disorder Focal Segmental Glomerulosclerosis (FSGS)
2025 Year in Review: Lymphoma
The Economics of Atopic Dermatitis: From Real-World Burden to Value- Driven Treatment Strategies
2025 Year in Review: Clostridioides difficile Infection
Equitable Management of Atopic Dermatitis: Treatment Considerations Across Patient Populations
2025 Year in Review: Neurofibromatosis Type 1 With Plexiform Neurofibromas
Modernizing COPD Management: Guideline Evolution, Therapeutic Advances, and Practical Insights
Economic Impact of Intravenous Versus Subcutaneous Administration of Infliximab on Health System Finances and Operations
Clinical and Economic Value of ENTYVIO® (vedolizumab): Implications for Ulcerative Colitis and Crohn Disease Management
Managing HIV in 2025: Optimizing Treatment After Virologic Suppression
Exploring Emerging Therapies in Myasthenia Gravis
Clinical and Economic Considerations for Nivolumab-Based Therapy for Resectable Non–Small Cell Lung Cancer
Continuous Glucose Monitoring as a Driver of Quality and Value: Evidence and Perspectives from Clinical and Managed Care Leaders
The Role of TEVIMBRA® (tislelizumab-jsgr) in First-Line ESCC Treatment
